Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL22 immunotoxin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| BL22 immunotoxin | DRUG | - |
| antibody-drug conjugate therapy | PROCEDURE | - |
| immunotoxin therapy | PROCEDURE | - |
DISEASE CHARACTERISTICS: * Diagnosis of B-cell leukemia or lymphoma of 1 of the following types: * Chronic lymphocytic leukemia * Failed standard chemotherapy * Prolymphocytic leukemia * Failed standard chemotherapy * Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma ...
Top 20 of 60 competitors
BL22 immunotoxin is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for leukemia. It is a CD22-targeted binding agent studied in patients with refractory chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's lymphoma. It has completed one Phase 1 trial in the United States.
BL22 immunotoxin was studied for refractory chronic lymphocytic leukemia, prolymphocytic leukemia, and non-Hodgkin's lymphoma. The single Phase 1 trial enrolled 24 patients aged 18 years and older, with no healthy volunteers. It is investigational and has not been approved for any indication.
BL22 immunotoxin targets CD22, a binding agent target. Its development focused on CD22-positive B-cell malignancies, including refractory chronic lymphocytic leukemia, prolymphocytic leukemia, and non-Hodgkin's lymphoma. The Phase 1 trial used biomarker selection to enroll appropriate patients.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of BL22 immunotoxin. The company sponsored the Phase 1 study of the CD22-targeted agent in leukemia and lymphoma patients.
BL22 immunotoxin is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The study was uncontrolled, non-randomized, and not double blinded, enrolling 24 patients. It is investigational and not approved by the FDA.
BL22 immunotoxin was evaluated in one completed Phase 1 trial, NCT00126646, titled BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma. The trial enrolled 24 patients in the United States and is no longer active.